{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:09:11Z","timestamp":1790168951591,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Cruces Rheumatology Association"},{"name":"Spanish Foundation for Rheumatology"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.rdc.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T19:07:06Z","timestamp":1569524826000},"page":"583-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Gout"],"prefix":"10.1016","volume":"45","author":[{"given":"Fernando","family":"Perez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2019.08.001_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.rdc.2014.01.003","article-title":"Clinical manifestations and diagnosis of gout","volume":"40","author":"Perez-Ruiz","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"issue":"7081","key":"10.1016\/j.rdc.2019.08.001_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.rdc.2019.08.001_bib3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.27356","article-title":"Cellular characterization of the gouty tophus: a quantitative analysis","volume":"62","author":"Dalbeth","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2019.08.001_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/0002-9343(74)90634-2","article-title":"Milestones in the treatment of gout","volume":"56","author":"Y\u00fc","year":"1974","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.rdc.2019.08.001_bib5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2019.08.001_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2019.08.001_bib7","first-page":"ii9","article-title":"Treating to target: an strategy to cure gout","volume":"49","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2019.08.001_bib8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"suppl_1","key":"10.1016\/j.rdc.2019.08.001_bib9","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/rheumatology\/kex442","article-title":"Treat to target in gout","volume":"57","author":"Perez-Ruiz","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2019.08.001_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semarthrit.2010.09.003","article-title":"Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers","volume":"40","author":"Stamp","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2019.08.001_bib11","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/art.1780341203","article-title":"Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout","volume":"34","author":"McCarthy","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2019.08.001_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8","article-title":"Gout: six-year follow-up of probenecid (benemid) therapy","volume":"2","author":"Bartels","year":"1959","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2019.08.001_bib13","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II. Management. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2019.08.001_bib14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2019.08.001_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","article-title":"Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative","volume":"73","author":"Sivera","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2019.08.001_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2019.08.001_bib17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2019.08.001_bib18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(57)91541-6","article-title":"Protracted uricosuric therapy in tophaceous gout","volume":"2","author":"Gutman","year":"1957","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rdc.2019.08.001_bib19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/art.1780090306","article-title":"Effects of allopurinol, a xanthine-oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout","volume":"9","author":"Goldfarb","year":"1967","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2019.08.001_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2019.08.001_bib21","first-page":"1888","article-title":"Ultrasonographic measurement of tophi as an outcome measure for chronic gout","volume":"34","author":"Perez-Ruiz","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2019.08.001_bib22","article-title":"Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study","author":"Ebstein","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.rdc.2019.08.001_bib23","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10067-017-3729-z","article-title":"Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking","volume":"36","author":"Modjinou","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2019.08.001_bib24","author":"Terkeltaub"},{"issue":"1","key":"10.1016\/j.rdc.2019.08.001_bib25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","article-title":"Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase","volume":"20","author":"Mandell","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2019.08.001_bib26","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2019.08.001_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11606-017-4233-5","article-title":"Effects of discontinuation of urate-lowering therapy: a systematic review","volume":"33","author":"Beslon","year":"2018","journal-title":"J\u00a0Gen Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2019.08.001_bib28","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2019.08.001_bib29","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A\u00a0two-stage approach to the treatment of hyperuricemia in gout: the \"Dirty Dish\" hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2019.08.001_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7326\/M16-2401","article-title":"To treat or not to treat (to target) in gout","volume":"166","author":"Neogi","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2019.08.001_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.rdc.2019.08.001_bib32","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British Society for Rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2019.08.001_bib33","author":"American College of Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2019.08.001_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.40031","article-title":"Do not let gout apathy lead to gouty arthropathy","volume":"69","author":"Fitzgerald","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2019.08.001_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22741","article-title":"Development of preliminary remission criteria for gout using delphi and 1000minds consensus exercises","volume":"68","author":"de","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.rdc.2019.08.001_bib36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.berh.2016.10.010","article-title":"Imaging of gout: new tools and biomarkers?","volume":"30","author":"Araujo","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.rdc.2019.08.001_bib37","article-title":"Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved","author":"Thiele","year":"2009","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.rdc.2019.08.001_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jbspin.2014.03.011","article-title":"Ultrasound in gout: a useful tool for following urate-lowering therapy","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.rdc.2019.08.001_bib39","first-page":"385","article-title":"Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment?","volume":"33","author":"Peiteado","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2019.08.001_bib40","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/rmdopen-2015-000075","article-title":"Tophus resolution with pegloticase: a prospective dual-energy CT study","volume":"1","author":"Araujo","year":"2015","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.rdc.2019.08.001_bib41","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar4343","article-title":"Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study","volume":"15","author":"Rajan","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2019.08.001_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2018.12.010","article-title":"Potential dangers of\u00a0serum urate-lowering therapy","author":"Perez-Gomez","year":"2019","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.rdc.2019.08.001_bib43","doi-asserted-by":"crossref","first-page":"e0210085","DOI":"10.1371\/journal.pone.0210085","article-title":"Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus","volume":"14","author":"Chang","year":"2019","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.rdc.2019.08.001_bib44","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2019.08.001_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12883-015-0273-9","article-title":"Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies","volume":"16","author":"Pakpoor","year":"2015","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2019.08.001_bib46","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2016-210767","article-title":"Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study","volume":"77","author":"Latourte","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X19300638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X19300638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:17:17Z","timestamp":1760181437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X19300638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0889857X19300638"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2019.08.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gout","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}